Volume | 667 |
|
|||||
News | - | ||||||
Day High | 4.1299 | Low High |
|||||
Day Low | 3.75 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Xenetic Biosciences Inc | XBIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.75 | 3.75 | 4.1299 | 4.0899 | 3.7759 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
20 | 667 | US$ 4.04 | US$ 2,696 | - | 2.55 - 5.97 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 2 | US$ 3.81 | USD |
Xenetic Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.3M | 1.54M | - | 2.54M | -4.14M | -2.68 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Xenetic Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XBIO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.06 | 4.30 | 3.74 | 3.81 | 2,569 | 0.0299 | 0.74% |
1 Month | 3.85 | 4.74 | 3.74 | 4.34 | 6,881 | 0.2399 | 6.23% |
3 Months | 3.66 | 4.74 | 3.3301 | 4.16 | 5,747 | 0.4299 | 11.75% |
6 Months | 3.06 | 4.74 | 2.8696 | 3.86 | 5,199 | 1.03 | 33.66% |
1 Year | 4.621 | 5.97 | 2.55 | 3.64 | 17,122 | -0.5311 | -11.49% |
3 Years | 19.60 | 56.80 | 2.401 | 29.40 | 941,726 | -15.51 | -79.13% |
5 Years | 14.30 | 168.895 | 2.401 | 26.49 | 746,185 | -10.21 | -71.40% |
Xenetic Biosciences Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. |